Lacosamide

Generic Name
Lacosamide
Brand Names
Motpoly, Vimpat, Lacosamide Adroiq, Lacosamide Accord, Lacosamide UCB
Drug Type
Small Molecule
Chemical Formula
C13H18N2O3
CAS Number
175481-36-4
Unique Ingredient Identifier
563KS2PQY5
Background

Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focu...

Indication

Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.

Associated Conditions
Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Status Epilepticus
Associated Therapies
-
Clinical Trials
Related News

Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee

Phase 2
Terminated
Conditions
Osteoarthritis
Interventions
Other: Placebo
Drug: lacosamide
First Posted Date
2007-06-13
Last Posted Date
2017-08-28
Lead Sponsor
UCB Pharma
Target Recruit Count
194
Registration Number
NCT00485472

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

Phase 2
Completed
Conditions
Migraine
Interventions
Other: Placebo
Drug: Lacosamide
First Posted Date
2007-02-27
Last Posted Date
2018-07-17
Lead Sponsor
UCB Pharma
Target Recruit Count
218
Registration Number
NCT00440518

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Phase 2
Completed
Conditions
Fibromyalgia Syndrome
Interventions
Other: Placebo
Drug: Lacosamide
First Posted Date
2006-11-22
Last Posted Date
2018-07-18
Lead Sponsor
UCB Pharma
Target Recruit Count
159
Registration Number
NCT00401830

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Phase 2
Completed
Conditions
Chronic Refractory Neuropathic Pain
Interventions
Drug: Lacosamide
First Posted Date
2005-10-12
Last Posted Date
2017-08-28
Lead Sponsor
UCB Pharma
Target Recruit Count
7
Registration Number
NCT00237458

A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

Phase 2
Completed
Conditions
Diabetic Neuropathy
Interventions
Drug: lacosamide
First Posted Date
2005-10-10
Last Posted Date
2018-07-17
Lead Sponsor
UCB Pharma
Target Recruit Count
451
Registration Number
NCT00235443

A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy

Phase 3
Completed
Conditions
Painful Diabetic Neuropathy
Interventions
Drug: Lacosamide
First Posted Date
2005-09-22
Last Posted Date
2023-07-24
Lead Sponsor
UCB Pharma
Target Recruit Count
371
Registration Number
NCT00220337
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy